tiprankstipranks
Advertisement
Advertisement
Disc Medicine: Outperform Rating Reiterated as Advancing Rare-Hematology Pipeline Supports Unchanged $100 Price Target
PremiumRatingsDisc Medicine: Outperform Rating Reiterated as Advancing Rare-Hematology Pipeline Supports Unchanged $100 Price Target
2M ago
Disc Medicine presents updated data from RALLY-MF trial at ASCO
Premium
The Fly
Disc Medicine presents updated data from RALLY-MF trial at ASCO
2M ago
Disc Medicine price target raised to $80 from $75 at Morgan Stanley
Premium
The Fly
Disc Medicine price target raised to $80 from $75 at Morgan Stanley
3M ago
FDA review process for accelerated approval narrows, less predictable, WSJ says
PremiumThe FlyFDA review process for accelerated approval narrows, less predictable, WSJ says
5M ago
Disc Medicine price target raised to $79 from $78 at Wells Fargo
Premium
The Fly
Disc Medicine price target raised to $79 from $78 at Wells Fargo
5M ago
Disc Medicine Implements Restructuring Following FDA Response
Premium
Company Announcements
Disc Medicine Implements Restructuring Following FDA Response
5M ago
Disc Medicine reports FY25 EPS ($6.01) vs ($3.96) last year
PremiumThe FlyDisc Medicine reports FY25 EPS ($6.01) vs ($3.96) last year
5M ago
Disc Medicine’s RALLY-IBD Trial Puts a Spotlight on Anemia Relief in IBD Patients
Premium
Company Announcements
Disc Medicine’s RALLY-IBD Trial Puts a Spotlight on Anemia Relief in IBD Patients
5M ago
Disc Medicine price target lowered to $88 from $110 at Wedbush
Premium
The Fly
Disc Medicine price target lowered to $88 from $110 at Wedbush
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100